JP2025507929A - インスリン融合タンパク質 - Google Patents

インスリン融合タンパク質 Download PDF

Info

Publication number
JP2025507929A
JP2025507929A JP2024552283A JP2024552283A JP2025507929A JP 2025507929 A JP2025507929 A JP 2025507929A JP 2024552283 A JP2024552283 A JP 2024552283A JP 2024552283 A JP2024552283 A JP 2024552283A JP 2025507929 A JP2025507929 A JP 2025507929A
Authority
JP
Japan
Prior art keywords
fusion protein
proinsulin
canine
sequence
feline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507929A5 (https=
Inventor
ジェイ． バスフィールド，サマンサ
ジェイ． ウィルソン，マシュー
Original Assignee
スカウト バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スカウト バイオ， インコーポレイテッド filed Critical スカウト バイオ， インコーポレイテッド
Publication of JP2025507929A publication Critical patent/JP2025507929A/ja
Publication of JP2025507929A5 publication Critical patent/JP2025507929A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024552283A 2022-03-01 2023-03-01 インスリン融合タンパク質 Pending JP2025507929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315296P 2022-03-01 2022-03-01
US63/315,296 2022-03-01
PCT/US2023/063510 WO2023168288A2 (en) 2022-03-01 2023-03-01 Insulin fusion protein

Publications (2)

Publication Number Publication Date
JP2025507929A true JP2025507929A (ja) 2025-03-21
JP2025507929A5 JP2025507929A5 (https=) 2026-03-10

Family

ID=87884362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552283A Pending JP2025507929A (ja) 2022-03-01 2023-03-01 インスリン融合タンパク質

Country Status (11)

Country Link
US (1) US20250188144A1 (https=)
EP (1) EP4486796A4 (https=)
JP (1) JP2025507929A (https=)
KR (1) KR20240167718A (https=)
CN (1) CN119562965A (https=)
AU (1) AU2023228668A1 (https=)
CA (1) CA3245376A1 (https=)
CL (1) CL2024002605A1 (https=)
IL (1) IL315354A (https=)
MX (1) MX2024010693A (https=)
WO (1) WO2023168288A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173090B (zh) * 2025-05-21 2025-07-29 华中农业大学 猫血清白蛋白突变体、及其cho细胞表达方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2676932C (en) * 2007-02-01 2015-11-24 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
BR112014015156A2 (pt) * 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein

Also Published As

Publication number Publication date
CA3245376A1 (en) 2023-09-07
US20250188144A1 (en) 2025-06-12
KR20240167718A (ko) 2024-11-27
WO2023168288A2 (en) 2023-09-07
AU2023228668A1 (en) 2024-09-19
WO2023168288A3 (en) 2023-09-28
MX2024010693A (es) 2024-12-06
EP4486796A4 (en) 2026-03-04
IL315354A (en) 2024-11-01
CN119562965A (zh) 2025-03-04
EP4486796A2 (en) 2025-01-08
CL2024002605A1 (es) 2025-07-11

Similar Documents

Publication Publication Date Title
KR20180057609A (ko) Glp-1 및 대사성 질환 치료용 조성물에서 이의 용도
CN121575014A (zh) 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗
US20230405150A1 (en) Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines
JP7840319B2 (ja) Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
US20250388926A1 (en) Viral vector genome encoding an insulin fusion protein
US20240175054A1 (en) Composition and methods for the treatment of fabry disease
US20250188144A1 (en) Insulin fusion protein
JP2025508987A (ja) Ｇｌｐ－１受容体アゴニスト融合物の送達のためのａａｖベクター
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
US20240182925A1 (en) Insulin gene therapy to treat diabetes
CN116376921A (zh) 一种用于治疗糖尿病的aav载体及其用途
WO2024227445A2 (en) Engineered alpha-galactosidase a (α-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
HK40098913B (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
HK40098913A (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
CN117551636A (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
CN116199793A (zh) 一种长效重组犬胰岛素融合蛋白的制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260302